CISATRACURIUM BESYLATE Drug Patent Profile

Which patents cover Cisatracurium Besylate, and what generic alternatives are available?

Cisatracurium Besylate is a drug marketed by Accord Hlthcare, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hainan Poly, Hengrui Pharma, Hikma, Hospira, Meitheal, Piramal, Sagent Pharms Inc, Sandoz Inc, Somerset, Zydus Pharms, and Somerset Theraps Llc. and is included in twenty-six NDAs.

The generic ingredient in CISATRACURIUM BESYLATE is cisatracurium besylate. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cisatracurium Besylate

A generic version of CISATRACURIUM BESYLATE was approved as cisatracurium besylate by SANDOZ INC on February 3^rd, 2012.

Summary for CISATRACURIUM BESYLATE

US Patents:	0
Applicants:	16
NDAs:	26
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	13
Drug Prices:	Drug price information for CISATRACURIUM BESYLATE
DailyMed Link:	CISATRACURIUM BESYLATE at DailyMed

See drug prices for CISATRACURIUM BESYLATE

Recent Clinical Trials for CISATRACURIUM BESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Watim Medical & Dental College	NA
Second Affiliated Hospital of Nanchang University	Phase 4
Yichang Humanwell Pharmaceutical Co.,Ltd	Phase 4

See all CISATRACURIUM BESYLATE clinical trials

Pharmacology for CISATRACURIUM BESYLATE

Drug Class	Nondepolarizing Neuromuscular Blocker
Physiological Effect	Neuromuscular Nondepolarizing Blockade

Anatomical Therapeutic Chemical (ATC) Classes for CISATRACURIUM BESYLATE

M03AC	Other quaternary ammonium compounds
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

M03AC	Other quaternary ammonium compounds
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for CISATRACURIUM BESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NIMBEX PRESERVATIVE FREE	Injection	cisatracurium besylate	2 mg/mL, 10 mL vial	020551	1	2009-08-12
NIMBEX PRESERVATIVE FREE	Injection	cisatracurium besylate	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	020551	1	2009-08-04

US Patents and Regulatory Information for CISATRACURIUM BESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Somerset Theraps Llc	CISATRACURIUM BESYLATE PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	206791-001	Feb 20, 2019	AP	RX	No	No
Eugia Pharma	CISATRACURIUM BESYLATE PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	209665-001	Oct 27, 2020		DISCN	No	No
Zydus Pharms	CISATRACURIUM BESYLATE	cisatracurium besylate	INJECTABLE;INJECTION	213527-001	Sep 1, 2020		DISCN	No	No
Fresenius Kabi Usa	CISATRACURIUM BESYLATE PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	203182-001	Feb 26, 2015	AP	RX	No	No
Zydus Pharms	CISATRACURIUM BESYLATE	cisatracurium besylate	INJECTABLE;INJECTION	212171-002	Nov 4, 2019	AP	RX	No	No
Accord Hlthcare	CISATRACURIUM BESYLATE	cisatracurium besylate	INJECTABLE;INJECTION	205873-001	Jun 16, 2017		DISCN	No	No